Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MOTUS GI HOLDINGS, INC.

(MOTS)
  Report
Delayed Nasdaq  -  03:59 2022-09-26 pm EDT
2.380 USD   -3.25%
08/24Motus Gi : Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Form 8-K
PU
08/24Motus Gi Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
08/15HC Wainwright Adjusts Price Target on Motus GI Holdings to $11 From $20, Reiterates Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

06/23/2021 | 04:05pm EDT

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company’s Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (Nasdaq: NK) and Immunity Bio, Inc. (Nasdaq: IBRX).

"We are thrilled to welcome Sonja to our Board of Directors," commented David Hochman, Chairman of the Board of Directors of Motus GI. "Sonja brings strong financial and strategic experience, and a fresh perspective from an innovative leader in the biotechnology industry that we believe will be of great benefit as Motus GI prepares for its next stage of growth."

Ms. Nelson has accumulated financial, accounting, and public company experience during her time at several biotechnology, pharmaceutical, and consumer health product companies. Ms. Nelson is currently serving as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX). She moved into this position in March 2021, following the merger of ImmunityBio, Inc. and NantKwest, Inc., where she had served as the Chief Financial Officer for several years, and had held other senior financial positions in the company since 2015. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc.) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. Prior to AltheaDx, Inc., Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc). Prior to her time at Cadence, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.). Ms. Nelson began her career with KPMG LLP. She holds a Bachelor’s degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant (CPA).

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. For more information, visit www.motusgi.com and connect with the Company on TwitterLinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com


Primary Logo


© GlobeNewswire 2021
All news about MOTUS GI HOLDINGS, INC.
08/24Motus Gi : Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Form 8-K
PU
08/24Motus Gi Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
08/15HC Wainwright Adjusts Price Target on Motus GI Holdings to $11 From $20, Reiterates Buy..
MT
08/11Motus Gi : Reports Second Quarter 2022 Financial Results and Provides Business Update - Fo..
PU
08/11Transcript : Motus GI Holdings, Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11MOTUS GI HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
08/11Earnings Flash (MOTS) MOTUS GI HOLDINGS Posts Q2 Revenue $185,000, vs. Street Est of $0..
MT
08/11Motus Gi Holdings, Inc. : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
08/11Motus GI Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
08/11Motus GI Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
More news
Analyst Recommendations on MOTUS GI HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 1,17 M - -
Net income 2022 -20,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,38x
Yield 2022 -
Capitalization 7,13 M 7,13 M -
Capi. / Sales 2022 6,08x
Capi. / Sales 2023 1,33x
Nbr of Employees 30
Free-Float 92,5%
Chart MOTUS GI HOLDINGS, INC.
Duration : Period :
Motus GI Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOTUS GI HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,38 $
Average target price 12,20 $
Spread / Average Target 413%
EPS Revisions
Managers and Directors
Timothy P. Moran Chief Executive Officer & Director
Mark Pomeranz President, Chief Operating Officer & Director
Andrew L. Taylor Chief Financial Officer
David P. Hochman Chairman
Shervin Joe Korangy Independent Director
Sector and Competitors